Courier Capital LLC Makes New $482,000 Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Courier Capital LLC acquired a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 56,438 shares of the biopharmaceutical company’s stock, valued at approximately $482,000.

Several other hedge funds have also recently made changes to their positions in OCUL. Rhumbline Advisers lifted its position in Ocular Therapeutix by 39.1% during the 2nd quarter. Rhumbline Advisers now owns 211,301 shares of the biopharmaceutical company’s stock worth $1,445,000 after acquiring an additional 59,345 shares during the period. TD Asset Management Inc raised its stake in shares of Ocular Therapeutix by 40.3% in the second quarter. TD Asset Management Inc now owns 112,800 shares of the biopharmaceutical company’s stock worth $772,000 after purchasing an additional 32,400 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Ocular Therapeutix by 36.9% during the second quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 4,695 shares during the period. Arizona State Retirement System purchased a new stake in Ocular Therapeutix in the second quarter valued at approximately $193,000. Finally, Amalgamated Bank increased its holdings in Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,481 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OCUL has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank started coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the sale, the insider now directly owns 269,059 shares in the company, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.50% of the stock is owned by corporate insiders.

Ocular Therapeutix Stock Performance

OCUL opened at $8.12 on Tuesday. The firm has a fifty day moving average price of $9.22 and a 200 day moving average price of $8.95. Ocular Therapeutix, Inc. has a 1 year low of $3.76 and a 1 year high of $11.77. The stock has a market cap of $1.28 billion, a P/E ratio of -6.15 and a beta of 1.23. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.